• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Mastitis Market Size

    ID: MRFR/Pharma/3936-CR
    142 Pages
    Rahul Gotadki
    July 2019

    Mastitis Market Research Report Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), End User (Veterinary Centers and Hospital & Clinics) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Mastitis Market Infographic
    Purchase Options

    Mastitis Size

    Mastitis Market Size and Growth Highlights

    The mastitis market size refers to the extent or scale of the market related to mastitis, a condition that involves the inflammation of the breast tissue. This market size helps us understand how widespread or common mastitis is and how it impacts various healthcare aspects. In simple terms, the mastitis market size provides insights into the number of people affected by mastitis, the demand for related healthcare products and services, and the economic implications associated with managing and treating this condition. Mastitis is a common issue, especially among breastfeeding women, where the breast tissue becomes inflamed. The market size for mastitis reflects the number of individuals seeking medical attention or using products to address this condition. This information is valuable for healthcare professionals, researchers, and companies involved in developing solutions for mastitis. A larger market size indicates a higher demand for resources to manage and treat mastitis effectively. The mastitis market size can influence healthcare policies and strategies for addressing this condition. If the market size is significant, it may prompt increased investments in research, development of new treatments, and awareness campaigns. Understanding the market size is crucial for healthcare providers to allocate resources efficiently, ensuring that there are adequate facilities, healthcare professionals, and support systems to meet the needs of individuals dealing with mastitis. Moreover, the mastitis market size can have economic implications, as it involves factors such as healthcare expenditures, costs associated with treatments, and potential economic losses due to missed work or reduced productivity. By comprehending the market size, policymakers, healthcare professionals, and stakeholders can make informed decisions to enhance healthcare services, improve outcomes for those affected by mastitis, and contribute to overall public health.

    Mastitis Market Size Graph
    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    Market Summary

    As per MRFR analysis, the Mastitis Market Size was estimated at 27.58 USD Billion in 2024. The Mastitis industry is projected to grow from 32.2 in 2025 to 151.24 by 2035, exhibiting a compound annual growth rate (CAGR) of 16.73 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Mastitis Market is experiencing a dynamic shift driven by technological advancements and changing consumer demands.

    • Technological advancements in diagnostics are enhancing the detection and management of mastitis in both bovine and human populations.
    • North America remains the largest market for mastitis treatments, while the Asia-Pacific region is emerging as the fastest-growing market.
    • Bovine mastitis treatment, particularly through antibiotics, continues to dominate the market, whereas human mastitis solutions are witnessing rapid growth.
    • The rising incidence of mastitis in dairy cattle and growing awareness of animal health are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 27.58 (USD Billion)
    2035 Market Size 151.24 (USD Billion)
    CAGR (2025 - 2035) 16.73%
    Largest Regional Market Share in 2024 Europe

    Major Players

    <p>Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Cegelec (FR), Vetoquinol (FR), Huvepharma (BG), Phibro Animal Health (US), Dechra Pharmaceuticals (GB)</p>

    Market Trends

    The Mastitis Market is currently experiencing notable transformations driven by various factors. The increasing awareness regarding animal health and welfare is prompting dairy farmers to adopt better management practices. This shift is likely to enhance the overall quality of milk production, thereby influencing the demand for effective mastitis treatment solutions. Furthermore, advancements in veterinary medicine and technology are facilitating the development of innovative therapies and diagnostic tools, which may improve the detection and management of mastitis in livestock. As a result, stakeholders in the Mastitis Market are focusing on research and development to create more efficient products that cater to the evolving needs of the industry. In addition, the rising prevalence of mastitis in dairy herds is compelling producers to seek preventive measures and treatments. This trend suggests a growing market for both pharmaceuticals and alternative therapies aimed at reducing the incidence of this condition. Moreover, regulatory changes and increased scrutiny on antibiotic use in livestock are likely to drive the demand for non-antibiotic treatment options. Overall, the Mastitis Market appears poised for growth as it adapts to these emerging challenges and opportunities, fostering a more sustainable approach to dairy farming.

    Technological Advancements in Diagnostics

    The Mastitis Market is witnessing a surge in the adoption of advanced diagnostic tools. Innovations such as rapid testing kits and digital monitoring systems are enhancing the ability to detect mastitis early. This trend is likely to lead to timely interventions, reducing the overall impact of the disease on dairy production.

    Shift Towards Preventive Care

    There is a noticeable shift in focus towards preventive care within the Mastitis Market. Dairy producers are increasingly investing in management practices that aim to prevent mastitis outbreaks. This proactive approach may result in a decline in treatment costs and improved herd health.

    Regulatory Changes Impacting Treatment Options

    Regulatory frameworks surrounding antibiotic use in livestock are evolving, influencing the Mastitis Market. Stricter guidelines are prompting the development of alternative treatment options. This trend indicates a potential shift towards more sustainable practices in managing mastitis.

    <p>The increasing prevalence of mastitis in dairy herds underscores the urgent need for effective management strategies to enhance animal welfare and ensure the sustainability of dairy production.</p>

    U.S. Department of Agriculture (USDA)

    Mastitis Market Market Drivers

    Growing Awareness of Animal Health

    There is a notable increase in awareness regarding animal health, particularly among dairy farmers and consumers. This heightened awareness is driving the Mastitis Market as stakeholders recognize the importance of maintaining herd health for sustainable production. Educational initiatives and outreach programs have been implemented to inform farmers about the implications of mastitis on animal welfare and economic viability. Consequently, this awareness is fostering a demand for advanced diagnostic tools and treatment options, thereby stimulating growth within the Mastitis Market. The emphasis on animal welfare is expected to continue influencing purchasing decisions in the coming years.

    Increasing Demand for Dairy Products

    The rising demand for dairy products is a crucial factor propelling the Mastitis Market. As consumer preferences shift towards dairy consumption, the pressure on dairy producers to maintain high-quality milk production intensifies. This demand compels farmers to adopt effective mastitis management strategies to ensure optimal milk yield and quality. Reports suggest that the dairy market is projected to grow at a compound annual growth rate of 3.5 percent over the next five years. Consequently, the Mastitis Market is poised to benefit from this trend, as producers seek solutions to combat mastitis and enhance overall herd productivity.

    Advancements in Treatment Technologies

    Technological advancements in treatment options are significantly influencing the Mastitis Market. Innovations such as targeted therapies and improved antibiotic formulations are emerging, providing more effective solutions for managing mastitis. The introduction of non-antibiotic alternatives, including immunomodulators and herbal treatments, is also gaining traction. These advancements not only enhance treatment efficacy but also align with the growing demand for sustainable practices in livestock management. As a result, the Mastitis Market is likely to experience growth driven by the adoption of these novel technologies, which aim to improve animal health outcomes and reduce reliance on traditional antibiotics.

    Rising Incidence of Mastitis in Dairy Cattle

    The increasing incidence of mastitis in dairy cattle is a primary driver of the Mastitis Market. Reports indicate that mastitis affects approximately 30 percent of dairy herds, leading to significant economic losses. The condition not only reduces milk production but also increases veterinary costs and impacts milk quality. As dairy farmers seek to mitigate these losses, there is a growing demand for effective treatment and prevention solutions. This trend is likely to propel the Mastitis Market forward, as stakeholders invest in innovative therapies and management practices to address the rising prevalence of this disease.

    Regulatory Pressure for Sustainable Practices

    Regulatory frameworks are increasingly emphasizing sustainable practices in livestock management, which is impacting the Mastitis Market. Governments and organizations are implementing stricter guidelines regarding antibiotic use and animal welfare standards. This regulatory pressure is prompting dairy farmers to seek alternative solutions for mastitis management that align with sustainability goals. As a result, there is a growing market for innovative treatments and preventive measures that comply with these regulations. The Mastitis Market is likely to evolve in response to these changes, as stakeholders adapt to meet both regulatory requirements and consumer expectations for responsible dairy production.

    Market Segment Insights

    By Type: Bovine Mastitis (Largest) vs. Human Mastitis (Fastest-Growing)

    <p>The Mastitis Market shows a distinct segmentation in terms of type, with Bovine Mastitis holding a significant share owing to the large-scale cattle farming and dairy industry demands. This segment is prevalent due to the higher incidence of mastitis in cows, leading to increased treatment expenditures. On the other hand, Human Mastitis, while smaller in proportion, is witnessing rapid growth, driven by rising awareness of breast health issues and the increasing prevalence of mastitis in breastfeeding women.</p>

    <p>Bovine Mastitis (Dominant) vs. Human Mastitis (Emerging)</p>

    <p>Bovine Mastitis remains the dominant force in the Mastitis Market, primarily attributed to extensive dairy farming practices and the consequential need for effective treatment options. The focus on dairy production makes managing bovine mastitis critical for farmers, elevating the demand for veterinary solutions. Conversely, Human Mastitis is emerging rapidly, fueled by heightened awareness of breast health among postpartum women and an increase in healthcare access. This growth is characterized by the introduction of innovative therapies tailored for human patients, alongside educational initiatives aimed at reducing the stigma surrounding this condition, thus positioning it as a significant developing segment in the mastitis landscape.</p>

    By Treatment: Bovine Antibiotics (Largest) vs. Bovine Vaccines (Fastest-Growing)

    <p>In the Mastitis Market, the treatment segment showcases a diverse range of products designed to combat this prevalent dairy cattle disease. Bovine Antibiotics dominate the market due to their established efficacy and widespread use among dairy farmers, capturing a significant market share. In contrast, Bovine Vaccines, while currently smaller, are rapidly gaining traction as awareness of preventive health measures grows, thus representing a compelling shift in industry preferences.</p>

    <p>Bovine Antibiotics (Dominant) vs. Bovine Vaccines (Emerging)</p>

    <p>Bovine Antibiotics remain the cornerstone of mastitis treatment offerings, valued for their effectiveness in managing infections and promoting bovine health. They have a strong presence due to familiarity among veterinarians and farmers, contributing to their dominant status in the market. However, Bovine Vaccines are emerging as a vital alternative, providing a proactive approach to mastitis management. Their rise is fueled by increasing demand for preventive health solutions, with advancements in vaccine technology enhancing their efficacy and appeal. Farmers are progressively inclined to invest in vaccines to minimize antibiotic use, thus promoting a shift toward holistic herd health management.</p>

    By End User: Veterinary Centers (Largest) vs. Hospitals & Clinics (Fastest-Growing)

    <p>In the Mastitis Market, the distribution of market share among end users reveals a dominant presence of veterinary centers, which are the largest segment owing to their specialized focus on animal health care, particularly in the management of mastitis in livestock. Veterinary centers provide dedicated services and expertise, leading to significant consumer preference in the market. Conversely, hospitals and clinics, while smaller in share, are gaining traction as they increasingly incorporate veterinary services and health management solutions that address mastitis treatments.</p>

    <p>End Users: Veterinary Centers (Dominant) vs. Hospitals & Clinics (Emerging)</p>

    <p>Veterinary centers play a crucial role in the Mastitis Market, characterized by their specialized approach to the treatment and prevention of mastitis in dairy cattle and other livestock. This segment is recognized for its focused expertise, offering tailored solutions and veterinary services that ensure enhanced animal health and productivity. In contrast, hospitals and clinics represent an emerging segment, expanding their services to include mastitis treatment. They benefit from integrating advanced medical technology and collaborative healthcare approaches, catering to a growing demand for comprehensive animal health services, thus indicating potential for rapid growth.</p>

    Get more detailed insights about Mastitis Market Research Report - Forecast till 2032

    Regional Insights

    Key Companies in the Mastitis Market market include

    Industry Developments

    • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
    • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
    • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Future Outlook

    Mastitis Market Future Outlook

    <p>The Mastitis Market is projected to grow at a 16.73% CAGR from 2024 to 2035, driven by advancements in treatment technologies and increasing awareness among dairy farmers.</p>

    New opportunities lie in:

    • <p>Development of telemedicine platforms for remote diagnosis and treatment monitoring.</p>
    • <p>Investment in AI-driven analytics for early detection of mastitis.</p>
    • <p>Expansion of organic and natural treatment product lines to meet consumer demand.</p>

    <p>By 2035, the Mastitis Market is expected to achieve substantial growth, reflecting evolving industry dynamics.</p>

    Market Segmentation

    Mastitis Market Type Outlook

    • Bovine Mastitis
    • Human Mastitis

    Mastitis Market End User Outlook

    • Veterinary Centers
    • Hospitals & Clinics

    Mastitis Market Treatment Outlook

    • Bovine Antibiotics
    • Bovine Vaccines
    • Human Pain Relievers
    • Human Antibiotics

    Report Scope

    MARKET SIZE 202427.58(USD Billion)
    MARKET SIZE 202532.2(USD Billion)
    MARKET SIZE 2035151.24(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)16.73% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in diagnostic technologies enhance early detection and treatment options in the Mastitis Market.
    Key Market DynamicsRising demand for effective mastitis treatments drives innovation and competition among pharmaceutical and biotechnology companies.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&amp;D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    1. Report Prologue
    2. Market Introduction
      1. Definition 19
      2. Scope of the Study 19
      3. Research Objective 19
      4. Assumptions & Limitations 19
        1. Assumptions 19
        2. Limitations 19
        3. Market Structure 20
    3. Research Methodology
      1. Primary Research Methodology 22
      2. Secondary Research Methodology 24
      3. Market Size Estimation 25
      4. Forecast Model 25
    4. Market Dynamics
      1. Introduction 27
      2. Drivers 28
        1. Rising Cases of Breast Cancer 28
        2. Increasing Rate of Pregnancy 28
        3. Unhygienic Barn Conditions Causing Contagious Mastitis in Bovines 28
      3. Restraints 29
        1. Lack of Awareness 29
        2. Complications in Diagnosis due to Similar Symptoms of Breast Cancer & Mastitis 29
      4. Opportunity 29
        1. Entering Developing Economies 29
      5. Macroeconomics 29
        1. Trends in Mastitis 30
    5. Market Factor Analysis
      1. Porter’s Five Forces Model 32
        1. Bargaining Power of Suppliers 32
        2. Bargaining Power of Buyers 33
        3. Threat of New Entrants 33
        4. Threat of Substitutes 33
        5. Intensity of Rivalry 33
      2. Value Chain Analysis 34
        1. R&D & Designing 34
        2. Manufacturing 34
        3. Distribution & Sales 34
        4. Post-Sales Services 34
      3. Investment Opportunities 35
      4. Price Analysis 35
    6. Global Mastitis Market, By Type
      1. Introduction 37
      2. Bovine 38
        1. Contagious Mastitis 38
        2. Environmental Mastitis 39
        3. Opportunist Mastitis 39
      3. Human 40
        1. Non-Infectious Mastitis 40
        2. Infectious Mastitis 41
    7. Global Mastitis Market, By Treatment
      1. Introduction 43
      2. Bovine 44
        1. Antibiotics 44
        2. Vaccines 44
      3. Human 45
        1. Pain Relievers 45
        2. Antibiotics 45
    8. Global Mastitis Market, By End User
      1. Introduction 47
      2. Veterinary Centers 48
      3. Hospital & Clinics 48
    9. Global Mastitis Market, By Region
      1. Introduction 50
      2. Americas 51
        1. North America 54
        2. South America 60
      3. Europe 62
        1. Western Europe 64
        2. Eastern Europe 79
      4. Asia-Pacific 81
        1. Japan 83
        2. China 85
        3. India 87
        4. Australia 89
        5. South Korea 91
        6. Rest of Asia-Pacific 93
      5. Middle East & Africa 95
        1. Saudi Arabia 97
        2. United Arab Emirates 99
        3. Kuwait 101
        4. Oman 103
        5. Qatar 105
        6. Rest of Middle East 107
    10. Competitive Landscape
      1. Competitive Scenario 110
        1. Introduction 110
    11. Company Profiles
      1. Bayer AG 113
        1. Company Overview 113
        2. Financial Overview 113
        3. Products Offering 114
        4. Key Developments 114
        5. SWOT Analysis 114
        6. Key Strategy 114
      2. BioNumerik Pharmaceuticals Inc 115
        1. Company Overview 115
        2. Financial Overview 115
        3. Products/Services Offered 115
        4. Key Developments 115
        5. SWOT Analysis 116
        6. Key Strategy 116
      3. Oncothyreon Inc 117
        1. Company Overview 117
        2. Financial Overview 117
        3. Products/Services Offered 117
        4. Key Developments 117
        5. SWOT Analysis 118
        6. Key Strategy 118
      4. Oncogenex 119
        1. Company Overview 119
        2. Financial Overview 119
        3. Products/Services Offered 119
        4. Key Developments 119
        5. SWOT Analysis 119
        6. Key Strategy 120
      5. Apthera Inc. 121
        1. Company Overview 121
        2. Financial Overview 121
        3. Products/Services Offered 121
        4. Key Developments 121
        5. SWOT Analysis 121
        6. Key Strategy 122
      6. Zoetis Inc 123
        1. Company Overview 123
        2. Financial Overview 123
        3. Products/Services Offered 124
        4. Key Developments 124
        5. SWOT Analysis 124
        6. Key Strategy 124
      7. Boehringer Ingelheim GmbH 125
        1. Company Overview 125
        2. Financial Overview 125
        3. Products/Services Offered 126
        4. Key Developments 126
        5. SWOT Analysis 126
        6. Key Strategy 126
      8. Merck Co. & Inc 127
        1. Company Overview 127
        2. Financial Overview 127
        3. Products/Services Offered 128
        4. Key Developments 128
        5. SWOT Analysis 128
        6. Key Strategy 128
      9. Astellas Pharma Inc 129
        1. Company Overview 129
        2. Financial Overview 129
        3. Products/Services Offered 130
        4. Key Developments 130
        5. SWOT Analysis 130
        6. Key Strategy 130
      10. Pfizer Inc. 131
        1. Company Overview 131
        2. Financial Overview 131
        3. Products/Services Offered 132
        4. Key Developments 132
        5. SWOT Analysis 132
        6. Key Strategy 132
      11. Novartis AG 133
        1. Company Overview 133
        2. Financial Overview 133
        3. Products/Services Offered 134
        4. Key Developments 134
        5. SWOT Analysis 134
        6. Key Strategy 134
      12. Sanofi SA 135
        1. Company Overview 135
        2. Financial Overview 135
        3. Products/Services Offered 136
        4. Key Developments 136
        5. SWOT Analysis 136
        6. Key Strategy 136
      13. F. Hoffmann-La Roche AG 137
        1. Company Overview 137
        2. Financial Overview 137
        3. Products/Services Offered 138
        4. Key Developments 138
        5. SWOT Analysis 138
        6. Key Strategy 138
    12. Appendix
      1. Discussion Blue Print 140
      2. References 141
    13. List of Tables
    14. MARKET SYNOPSIS 17
    15. PRIMARY INTERVIEWS 23
    16. GLOBAL MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 37
    17. GLOBAL MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 38
    18. GLOBAL MASTITIS MARKET FOR BOVINE, BY REGION 2020–2027 (USD MILLION) 38
    19. GLOBAL MASTITIS MARKET FOR CONTAGIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 38
    20. GLOBAL MASTITIS MARKET FOR ENVIRONMENTAL MASTITIS, BY REGION 2020–2027 (USD MILLION) 39
    21. GLOBAL MASTITIS MARKET FOR OPPORTUNIST MASTITIS, BY REGION 2020–2027 (USD MILLION) 39
    22. GLOBAL MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 40
    23. GLOBAL MASTITIS MARKET FOR HUMAN, BY REGION 2020–2027 (USD MILLION) 40
    24. GLOBAL MASTITIS MARKET FOR NON–INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 40
    25. GLOBAL MASTITIS MARKET FOR INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 41
    26. GLOBAL MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 43
    27. GLOBAL MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 44
    28. GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION TYPE 2020–2027 (USD MILLION) 44
    29. GLOBAL MASTITIS MARKET FOR VACCINES, BY REGION 2020–2027 (USD MILLION) 44
    30. GLOBAL MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 45
    31. GLOBAL MASTITIS MARKET FOR PAIN RELIEVERS, BY REGION TYPE 2020–2027 (USD MILLION) 45
    32. GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION 2020–2027 (USD MILLION) 45
    33. GLOBAL MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 47
    34. GLOBAL MASTITIS MARKET FOR VETERINARY CENTRES, BY REGION 2020–2027 (USD MILLION) 48
    35. GLOBAL MASTITIS MARKET FOR HOSPITAL & CLINICS, BY REGION 2020–2027 (USD MILLION) 48
    36. GLOBAL MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51
    37. AMERICAS MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51
    38. AMERICAS MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 52
    39. AMERICAS MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 52
    40. AMERICAS MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 52
    41. AMERICAS MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 52
    42. AMERICAS MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53
    43. AMERICAS MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53
    44. AMERICAS MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 53
    45. NORTH AMERICA MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 54
    46. NORTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 54
    47. NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 54
    48. NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 55
    49. NORTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 55
    50. NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55
    51. NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55
    52. NORTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 56
    53. US MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 56
    54. US MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 56
    55. US MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 56
    56. US MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 57
    57. US MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57
    58. US MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57
    59. US MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 57
    60. CANADA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 58
    61. CANADA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 58
    62. CANADA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 58
    63. CANADA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 58
    64. CANADA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59
    65. CANADA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59
    66. CANADA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 59
    67. SOUTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 60
    68. SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 60
    69. SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 60
    70. SOUTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 60
    71. SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61
    72. SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61
    73. SOUTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 61
    74. EUROPE MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 62
    75. EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 62
    76. EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 62
    77. EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 63
    78. EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 63
    79. EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63
    80. EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63
    81. EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 64
    82. WESTERN EUROPE MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 64
    83. WESTERN EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 65
    84. WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 65
    85. WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 65
    86. WESTERN EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 65
    87. WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66
    88. WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66
    89. WESTERN EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 66
    90. GERMANY MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 67
    91. GERMANY MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 67
    92. GERMANY MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 67
    93. GERMANY MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 67
    94. GERMANY MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68
    95. GERMANY MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68
    96. GERMANY MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 68
    97. FRANCE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 69
    98. FRANCE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 69
    99. FRANCE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 69
    100. FRANCE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 69
    101. FRANCE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70
    102. FRANCE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70
    103. FRANCE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 70
    104. UK MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 71
    105. UK MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 71
    106. UK MASTITIS MARKET FOR HUMAN, BY TYPE 2020&
      1. '

    Mastitis Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions